ATE546735T1 - Pro-epil-expressionsniveau in einer biologischen probe als biomarker für hodenkrebs, insbesondere in kombination mit den biomarkern hcgbeta und afp - Google Patents

Pro-epil-expressionsniveau in einer biologischen probe als biomarker für hodenkrebs, insbesondere in kombination mit den biomarkern hcgbeta und afp

Info

Publication number
ATE546735T1
ATE546735T1 AT09738132T AT09738132T ATE546735T1 AT E546735 T1 ATE546735 T1 AT E546735T1 AT 09738132 T AT09738132 T AT 09738132T AT 09738132 T AT09738132 T AT 09738132T AT E546735 T1 ATE546735 T1 AT E546735T1
Authority
AT
Austria
Prior art keywords
expression level
pro
epil
biomarker
combination
Prior art date
Application number
AT09738132T
Other languages
English (en)
Inventor
Dominique Bellet
Alain Pecking
Sophie Richon
Felice Petraglia
Original Assignee
Univ Paris Descartes
Inst Curie
Roussy Inst Gustave
Univ Siena
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Paris Descartes, Inst Curie, Roussy Inst Gustave, Univ Siena, Centre Nat Rech Scient filed Critical Univ Paris Descartes
Application granted granted Critical
Publication of ATE546735T1 publication Critical patent/ATE546735T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT09738132T 2008-04-28 2009-04-28 Pro-epil-expressionsniveau in einer biologischen probe als biomarker für hodenkrebs, insbesondere in kombination mit den biomarkern hcgbeta und afp ATE546735T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4841208P 2008-04-28 2008-04-28
PCT/EP2009/055100 WO2009133088A1 (en) 2008-04-28 2009-04-28 PRO-EPIL EXPRESSION LEVEL IN A BIOLOGICAL SAMPLE AS TESTICULAR CANCER BIOMARKER, PARTICULARLY IN COMBINATION WITH THE HCGβ AND AFP BIOMARKERS

Publications (1)

Publication Number Publication Date
ATE546735T1 true ATE546735T1 (de) 2012-03-15

Family

ID=40801785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09738132T ATE546735T1 (de) 2008-04-28 2009-04-28 Pro-epil-expressionsniveau in einer biologischen probe als biomarker für hodenkrebs, insbesondere in kombination mit den biomarkern hcgbeta und afp

Country Status (5)

Country Link
US (1) US20110105365A1 (de)
EP (1) EP2281195B1 (de)
AT (1) ATE546735T1 (de)
ES (1) ES2380552T3 (de)
WO (1) WO2009133088A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2653870A1 (de) 2012-04-17 2013-10-23 Universite Paris Descartes Verfahren zur Auswahl von Serumbiomarkern eipigenetischer Veränderungen, insbesondere der globalen Hypomethylierung und ihre Verwendungen
CN115927333B (zh) * 2022-10-27 2025-05-06 中国科学技术大学 piR-36249基因类似物及其在预防和治疗癌症中的用途
CN119410774B (zh) * 2024-11-01 2025-06-03 上海爱谱蒂康生物科技有限公司 一种生物标志物组合及其在预测睾丸癌风险中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2721033B1 (fr) * 1994-06-13 1996-08-30 Roussy Inst Gustave Nouvelle protéine dénommée placentine, procédé de préparation de cette protéine et composition pharmaceutique la contenant, ADN codant pour ladite protéine.
FR2767326B1 (fr) * 1997-08-14 2001-06-22 Roussy Inst Gustave Identification et localisation de polypeptides epil exprimes codes par le gene insl4 et leurs applications

Also Published As

Publication number Publication date
EP2281195A1 (de) 2011-02-09
WO2009133088A1 (en) 2009-11-05
EP2281195B1 (de) 2012-02-22
US20110105365A1 (en) 2011-05-05
ES2380552T3 (es) 2012-05-16

Similar Documents

Publication Publication Date Title
MX368394B (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
GB201009641D0 (en) Methods of monitoring conditions by sequence analysis
NZ624816A (en) Ratio based biomarkers and methods of use thereof
ATE554389T1 (de) Apex als marker für lungenkrebs
EP4083233A3 (de) Verfahren zur verwendung von genexpression zur bestimmung der prognose von prostatakrebs
WO2011072177A3 (en) Biomarker assay for diagnosis and classification of cardiovascular disease
AR084723A1 (es) microARN (miARN) COMO BIOMARCADOR PARA LA IDENTIFICACION DEL CANCER COLORRECTAL FAMILIAR Y NO FAMILIAR
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MX2011011571A (es) Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2008122447A3 (en) Dna methylation assay for the diagnosis or prognosis of medical conditions
EP1930445A4 (de) Kit und verfahren zum nachweis von urothelkarzinom
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ES2530574T3 (es) Biomarcadores asociados a la nefropatía
WO2013119279A3 (en) Assays and methods for the diagnosis of ovarian cancer
WO2011049322A3 (ko) 유방암 진단을 위한 유방암 특이적 메틸화 마커 유전자의 메틸화 검출방법
Becker Improved methods and standards for telomerase detection: quantitative histopathology using antibody staining
Li et al. Aggregation-Induced Emission Probe/Graphene Oxide Aptasensor for Label-free and" turn-on" fluorescent detection of cancerous exosomes
Becker Improved methods and standards for telomerase assay: Quantitative histopathology using antibody staining